My current waves on 
MRK
would love some feedback, this catalyst and original chart was brought up originally by @tomikazi
It broke out of the downtrend channel and now is in wave 1.
Has a catalyst on Wednesday 1/20/21
PDUFA VII Decision for MRK's Vericiguat:
Merck Seeks Approval For Heart Failure Drug
Company: Merck & Co., Inc. (NYSE: MRK)
Type of Application: NDA
Candidate: vericiguat
Indication: heart failure
Positive ER expected:
Merck & Co., Inc.'s earnings, with the lowest EPS estimate coming in at $1.32 and the highest estimate coming in at $1.38. Merck & Co., Inc. reported
earnings of $1.16 per share during the same quarter last year, which indicates a positive year over year growth rate of 16.4%. The firm is scheduled to issue
its next quarterly earnings report before the market opens on Thursday, February 4th. -Marketbeat
MRK would love some feedback, this catalyst and original chart was brought up originally by @tomikazi
It broke out of the downtrend channel and now is in wave 1.
Has a catalyst on Wednesday 1/20/21
PDUFA VII Decision for MRK's Vericiguat:
Merck Seeks Approval For Heart Failure Drug
Company: Merck & Co., Inc. (NYSE: MRK)
Type of Application: NDA
Candidate: vericiguat
Indication: heart failure
Positive ER expected:
Merck & Co., Inc.'s earnings, with the lowest EPS estimate coming in at $1.32 and the highest estimate coming in at $1.38. Merck & Co., Inc. reported
earnings of $1.16 per share during the same quarter last year, which indicates a positive year over year growth rate of 16.4%. The firm is scheduled to issue
its next quarterly earnings report before the market opens on Thursday, February 4th. -Marketbeat
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。